VCG
MRNA icon

Vantage Consulting Group’s Moderna MRNA Stock Holding History

Vantage Consulting Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,305
Closed -$246K – 207
2024
Q1 		$246K Sell
2,305
-607
-21% -$61.2K 0.16% 125
2023
Q4 		$290K Buy
2,912
+757
+35% +$63.7K 0.19% 94
2023
Q3 		$223K Buy
2,155
+287
+15% +$32K 0.15% 155
2023
Q2 		$227K Buy
1,868
+135
+8% +$18K 0.13% 173
2023
Q1 		$266K Buy
1,733
+382
+28% +$63K 0.15% 115
2022
Q4 		$243K Sell
1,351
-460
-25% -$75.2K 0.14% 142
2022
Q3 		$214K Sell
1,811
-78
-4% -$11.8K 0.13% 171
2022
Q2 		$270K Buy
1,889
+227
+14% +$32.4K 0.15% 97
2022
Q1 		$286K Buy
1,662
+648
+64% +$109K 0.11% 97
2021
Q4 		$258K Buy
1,014
+465
+85% +$136K 0.07% 168
2021
Q3 		$211K Buy
+549
New +$202K 0.05% 180
2021
Q1 		– Sell
-6
Closed -$1K – 998
2020
Q4 		$1K Buy
+6
New +$607 ﹤0.01% 1776

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vantage Consulting Group's MRNA Position: Q2 2024 in Review

Vantage Consulting Group sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,305 shares — an estimated $246K sold.

Vantage Consulting Group first reported a position in MRNA in Q4 2020 and held it in 12 quarters. The position peaked at $290K in Q4 2023. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Vantage Consulting Group reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 2,305 Moderna shares in Q2 2024, an estimated $246K.
  • Vantage Consulting Group first reported a position in Moderna in Q4 2020 and held it in 12 quarters.
  • Vantage Consulting Group's Moderna position peaked at $290K in Q4 2023.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Vantage Consulting Group's 13F filing for Q2 2024, filed 14 Aug 2024.